secwatch.observer — SEC 8-K summary
======================================

Issuer:     ILLUMINA, INC. (ILMN)
CIK:        0001110803
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001110803-23-000061
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Illumina CMO Phil Febbo departs Aug 7; CTO Alex Aravanis departs Aug 9, replaced by Steven Barnard
--------------------------------------------------------------------------------

- Dr. Phil Febbo, Chief Medical Officer, departed Illumina on August 7, 2023.
- Dr. Alex Aravanis, Chief Technology Officer, departing August 9 to pursue another opportunity.
- Dr. Steven Barnard appointed CTO effective immediately; Barnard joined Illumina in 1998 as first scientist.
- Barnard previously VP of Global Advanced Science, holds >100 patents, led NovaSeq X series development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1110803/000111080323000061/0001110803-23-000061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1110803/000111080323000061/ilmn-20230807.htm
  HTML page:      https://secwatch.observer/filing/0001110803-23-000061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer